Research summary ·
The 2026 British Society for Rheumatology guideline for the treatment of polymyalgia rheumatica.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This is a guideline from the British Society for Rheumatology. It covers how doctors treat polymyalgia rheumatica, or PMR. PMR is a common inflammatory condition in older adults. The guideline was built using set methods to weigh the evidence. It replaces the earlier 2009 guideline on PMR.
What they found
The main drugs for PMR are glucocorticoids, called GCs here. Many people with PMR flare up as the GC dose is lowered. Long use of GCs can cause harm. The guideline sets out key points on when to refer people to rheumatology. It covers how to start GCs and how to lower the dose. It gives options for a faster way to lower the dose. It also covers early use of methotrexate.
What it means for patients
The guideline says doctors can use IL-6 receptor blockers in some cases. These are for people who cannot lower their GC dose, or respond poorly. It says doctors give bone protection to all people with PMR. It stresses ongoing teaching and support for patients. Doctors are also to watch for harm from GCs. The aim is safe care that fits each person, with careful GC use.
Why it is not certain yet
The abstract does not give the evidence behind each key point. It does not say how strong each piece of evidence is. It does not give details on doses or timing. A guideline can only be as good as the studies behind it.
Source
The 2026 British Society for Rheumatology guideline for the treatment of polymyalgia rheumatica.
PubMed · PMID 42869454We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Polymyalgia rheumatica publications